While this arrangement is mostly a risk to the investors, there has been speculation that states could be pressured to meet their payment obligations using general fund revenue in the event of significant MSA payment reductions
To enable CMS to calculate the benchmark period manufacturer price and inflation rebate amounts for these NDC-9s, CMS is proposing in 428.202(c)(3) that for a Part D rebatable drug first approved or licensed on or before October 1, 2021, for which there are no quarters during the period beginning on January 1, 2021, and ending on September 30, 2021, for which AMP has been reported under section 1927(b)(3) of the Act, CMS would identify the payment amount benchmark period as the first calendar year, which would be no earlier than calendar year 2021, in which such drug has at least 1 quarter of AMP reported
Lastly, sections 1847A(i)(8)(D) and (E) of the Act ( preclude administrative and judicial review of the computation of the adjusted coinsurance and amounts paid to the provider under section 1833(a)(1)(EE)
The full-bodied blend is known for its robust and smoky flavor, the medium blend for its balanced flavor, and the mild blend for its smooth and light flavor
.jpg)
